Human metapneumovirus infection in hematopoietic stem cell transplant recipients

Debur, Maria C.; Vidal, Luíne Rosele Renaud; Stroparo, Elenice; Nogueira, Meri Bordignon; Almeida, Sérgio Monteiro de; Takahashi, Gislene A.; Rotta, Indianara; Pereira, Luciane Aparecida; Silveira, Clyete Santos da; Bonfim, Caroline Measso do; Raboni, Sônia Mara

doi:10.1111/j.1399-3062.2009.00465.x

Cited by 49 publications

(43 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…One prospective study found that 40% of HMPV infections in 22 adults with hematologic malignancies progressed from upper respiratory infection to pneumonia, with case-fatality close to 14% [9]. Other studies in HCT recipients have shown pneumonia rates of 28% and mortality rates of 0-4% [19-21*]. Among 163 HCT recipients who underwent BAL for the work-up of pulmonary infiltrates, HMPV was detected in BAL samples from 5 of 163 (3%) patients; 4 of the 5 died with acute respiratory failure highlighting the potential severity of HMPV pneumonia [52].…”

Section: Newly Discovered Respiratory Virusesmentioning

confidence: 99%

Changing epidemiology of respiratory viral infections in hematopoietic cell transplant recipients and solid organ transplant recipients

Renaud¹,

Campbell

2011

Current Opinion in Infectious Diseases

127

View full text Add to dashboard Cite

Purpose of review New respiratory viruses have been discovered in recent years and new molecular diagnostic assays have been developed that improve our understanding of respiratory virus infections. This article will review the changing epidemiology of these viruses after hematopoietic stem cell and solid organ transplantation. Recent findings Respiratory viruses are frequently detected in transplant recipients. A number of viruses have been newly discovered or emerged in the last decade, including human metapneumovirus, human bocavirus, new human coronaviruses and rhinoviruses, human polyomaviruses, and a new 2009 pandemic strain of influenza A/H1N1. The potential for these viruses to cause lower respiratory tract infections after transplantation varies, and is greatest for human metapneumovirus and H1N1 influenza, but appears to be limited for the other new viruses. Acute and long term complications in hematopoietic and solid organ transplant recipients are active areas of research. Summary Respiratory viral infections are frequently associated with significant morbidity following transplantation and are therefore of great clinical and epidemiologic interest. As new viruses are discovered, and more sensitive diagnostic methods are developed, defining the full impact of emerging respiratory viruses in transplant recipients must be elucidated by well-designed clinical studies.

show abstract

Section: Newly Discovered Respiratory Virusesmentioning

confidence: 99%

Changing epidemiology of respiratory viral infections in hematopoietic cell transplant recipients and solid organ transplant recipients

Renaud¹,

Campbell

2011

Current Opinion in Infectious Diseases

127

View full text Add to dashboard Cite

show abstract

“…10 A more recent report, however, described a mild course of illness and complete recovery from hMPV infection in HSCT recipients including children. 11 We conducted a retrospective study to describe the clinical features and severity of hMPV in pediatric oncology patients at The Hospital for Sick Children, Toronto, Canada.…”

mentioning

confidence: 99%

Human Metapneumovirus (hMPV) Infection in Children With Cancer

Ali

Baker²,

Richardson³

et al. 2013

Journal of Pediatric Hematology/Oncology

View full text Add to dashboard Cite

Human metapneumovirus (hMPV) has recently emerged as an important cause of lower respiratory tract infections in hospitalized children, causing severe pneumonia and respiratory failure among immunocompromised patients. We retrospectively examined 30 children diagnosed with cancer whose nasopharyngeal swabs were positive for hMPV by direct fluorescent testing over a 5-year period. In 16/30 (53.3%) children, infection was confined to the upper respiratory tract, whereas lower respiratory tract infection occurred in 46.7%. The median duration of respiratory illness was 6.5 days with a hospital admission rate of 66.6%. No mechanical ventilation was required because of hMPV infection. Bronchoalveolar lavage tested positive for hMPV in 1 patient requiring prolonged inhaled steroid and bronchodilator therapy. All children recovered completely from hMPV infection. hMPV causes upper and lower respiratory tract infections in immunocompromised children. Infections may result in significant disease but is usually not fatal. In the absence of specific anti-viral drug, good symptomatic therapy appears to be the optimal therapy.

show abstract

“…29 Other study data show that RBV does not reduce mortality in immunocompromised patients and is not effective against the virus. 30 Although case 1 in our series is an example of successful treatment against HMPV using oral RBV, this finding does not establish a beneficial effect of RBV against HMPV infection.…”

Section: Discussionmentioning

confidence: 71%